All News

Article

Selective Biologic Responses in Seropositive RA

Jack Cush, MD

The Journal of Rheuatology reports a pooled analysis of patients from 16 observational RA registries that examined the association between seropositivity (RF or ACPA) with biologic DMARDs responses; they showed better clinical responses when seropositive RA patients receive abatacept (ABA) o

Article

Are Women in Rheumatology Closing the Gap?

Jack Cush, MD

"Fierce, Formidable and Phenomenal" was the tag line used to introduce Vice-Presidential candidate, Kamala Harris. Her introduction followed a review of the increasing role of women in voting, society and politics in America. Has the same been realized by women in academic medicine and rheumatology? 

Dr. John Cush Tweet
RheumNow
ATS Abstract: n=616 survey contrasts rheums (57%) & pulmonologists (43%) beliefs on RA associated ILD. Both preferred to use steroids, MMF, RTX for RA-ILD, but Rheums tend avoid ADA & LEF. Rheums (17%) & Pulms (24%) think MTX a risk factor https://t.co/W5gbu84FBv
Dr. John Cush Tweet
RheumNow
Metanalysis of total elbow arthroplasty in RA - 38 studies, 2,118 TEAs w/ mean F/U of 819 mos - the implant failure & complication rates were 16% & 24%. Aseptic loosening was most common failure (9.5%). Higher failures in younger pts & unlinked design https://t.co/Pq2N1Kku60
U.S. FDA Tweet
US_FDA
To date, the FDA has currently authorized 218 tests under EUAs; these include 176 molecular tests, 39 antibody tests, and 3 antigen tests.
Peter Nash Tweet
drpnash
@RheumNow its time we stopped “seroneg RA” which are many diseases, like ANCA pos Vasculitis we should have ACPA pos RA and others - how many viral arthritides in our country “doing great” on SZP, PLAQ, or low dose MTX and reluctant to stop? #RA #Seronegative
Dr. John Cush Tweet
RheumNow
Mayo clinic: Theres a delay in diagnosing Seronegative RA - 1st joint swelling to diagnosis of RA was 187 days for seroneg vs 11 days for seropositive patients (P<.001). Seronegative RA less likely to achieve remission (28% vs 50% at 5 years) (P=.007) https://t.co/Hgewjmt1CL
Dr. John Cush Tweet
RheumNow
Study of 2 Canadian centers finds amongst 2095 patients taking biologics for #Psoriasis, 23 (1.1%) stopped their biologic for "COVID-19 related concerns". 5/23 restarted biologic for PSO flares. This included TNFi, inhibitors of IL17, IL12/23, IL23 https://t.co/gjSX4P0LMK
Dr. John Cush Tweet
RheumNow
Are there delays in Dx-ing RA? 2019 UK NHS study shows median delays from 1st Sx to seeing a rheumatologist was 27 weeks, with 20% seen w/in 1st 3 mos. Includes a patient delay (5.4 wks), GP delay (6.9 wks) & hospital delay (4.7 wks) https://t.co/vwNALZKkiR
Dr. John Cush Tweet
RheumNow
Study from 3 NYC lupus clinics compares flare rates in older SLE stopping HCQ (n 26) vs continuing HCQ (N 32) with no difference in lupus flare rates (19 vs 16%). Reasons for stopping HCQ: retinal toxicity 42%, pt preference 35%, adverse effects 15% https://t.co/7cVZbfJK68
Dr. John Cush Tweet
RheumNow
Filgotinib Decision Delayed by FDA. Instead of being the next approved RA drug, the FDA issued a complete response letter; citing concerns over sperm studies and the risk/benefit behind the 200 mg dose. Delay till 2021? 2022? https://t.co/6MHiGtOxCM
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×